Tag Archives: Concert Pharmaceuticals

← Older posts Newer posts →

Concert Pharma To Get $300M+ Per Drug in Celgene Pact

The past 15 months have turned into a partnership symphony for Concert Pharmaceuticals. On Monday, the Lexington, MA-based company snagged its latest collaborative partner, revealing that it will team with Celgene (NASDAQ: CELG) to use its technology— which adds deuterium elements into existing drugs to boost their abilities—to develop cancer and inflammation drugs. Concert has […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main | Tagged , , , , , , , , , , , , , | Comments Off on Concert Pharma To Get $300M+ Per Drug in Celgene Pact

East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist

Another act in a stark boardroom drama unfolded this week for a public pharmaceutical company in New Jersey, but brighter stories took center stage in the Massachusetts biomedical arena. —A sweeping executive shakeout continued at Optimer Pharmaceuticals on Wednesday as CEO Pedro Lichtinger agreed to resign, and was replaced by Henry McKinnell, the former CEO […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , | Comments Off on East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist

Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy

If there was ever an occasion to play some Miles Davis around a Boston biotech company’s office, today is the day. Lexington, MA-based Concert Pharmaceuticals has the right to play it cool, or at least crack a few music jokes, after striking a collaboration with another musically inspired company—Dublin, Ireland-based Jazz Pharmaceuticals (NASDAQ: JAZZ). The […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , | Comments Off on Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy

BG Medicine, Bottomline, 4s3 Bioscience Among the Week’s Dealmakers

Partnership news, funding announcements, and an acquisition made up the New England deals news in the past week. —Concert Pharmaceuticals sold a worldwide license of its psychiatric drug to California-based Avanir Pharmaceuticals (NASDAQ: AVNR). The Lexington, MA-based biotech received an undisclosed upfront payment and is eligible for more than $200 million in additional sales and […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on BG Medicine, Bottomline, 4s3 Bioscience Among the Week’s Dealmakers

Concert, Alere, TremRx, & More Names from Boston Life Sciences News

Acquisitions, licensing deals, and companies emerging from stealth mode made up the New England life sciences news this week. —My colleague Arlene took a closer look at the Alzheimer’s drugmaker Satori Pharmaceuticals, which last week scored a $15 million venture funding round. Cambridge, MA-based Satori is looking to an unusual source to develop Alzheimer’s drugs: […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on Concert, Alere, TremRx, & More Names from Boston Life Sciences News

SD Life Sciences (and Cleantech) Roundup: DexCom, Ligand, Genomatica

In addition to some advances on the life sciences front, we saw a flurry of developments among San Diego’s industrial biotechnology startups over the past week. —San Diego’s DexCom (Nasdaq: DXCM), which makes continuous glucose monitoring devices for patients with diabetes, acquired SweetSpot Diabetes Care, a Portland, OR, health IT company. DexCom said it will […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments

Concert Nabs $200M Deal From Avanir to Make Psych Drugs

Lexington, MA-based Concert Pharmaceuticals has found a second partner looking to take advantage of its technology for making deuterium-modified drugs. Concert is announcing today that Aliso Viejo, CA-based Avanir Pharmaceuticals (NASDAQ: AVNR) has bought a worldwide license to Concert’s experimental drug that modifies dextromethorphan as a treatment for neurological and psychiatric disorders. Concert is getting […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Diego blog main | Tagged , , , , , , , , , , | 7 Comments

Verastem, the 15-Month Old Christoph Westphal Venture in Cancer Stem Cells, Seeks IPO

Cambridge, MA-based Verastem has big names and big science on its side, which a lot of startups have, but now it’s doing something quite unconventional for a company that’s just 15 months old—it’s trying to go public. Verastem, the company led by former Sirtris Pharmaceuticals CEO Christoph Westphal and founded on science from MIT luminaries […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | 7 Comments

Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News

We didn’t bring you a life sciences roundup last Friday due to some time constraints, but some of the weeks’ headlines were too important to skip altogether. So here are two weeks worth of biotech profiles, partnership announcements, personnel moves, financing news, and more. —The American Chemical Society awarded its highest honor, the Priestley Medal, to […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News

Concert Pharmaceuticals Hits $4 Million Milestone in GSK Alliance

Lexington, MA-based Concert Pharmaceuticals announced today that it has moved three novel drug candidates forward in its pipeline—one of which earned it a $4 million milestone payment from GlaxoSmithKline (NYSE: GSK). The European drug giant allied with Concert on an HIV program in 2009, and the molecule, called CTP-298, is now the lead compound in […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , | 1 Comment← Older posts Newer posts →